Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300007 | 1.00 | CTSK (0.57) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL7000046 | 1.00 | CTSK (0.57) | CTSKCTSBCTSSCTSLABCB1 | |
| Leucine SCHEMBL14693625 | 0.92 | CTSK (0.52) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL16272898 | 0.91 | CTSK (0.57) | CTSKCTSBCTSSCTSLABCB1 | |
| Leucine SCHEMBL4294227 | 0.90 | CTSK (0.50) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL26312471 | 0.90 | CTSK (0.56) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL2302062 | 0.89 | CTSK (0.49) | CTSKCTSBCTSSCTSLABCB1 | |
| Leucine SCHEMBL2302063 | 0.89 | CTSK (0.49) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL11306130 | 0.89 | CTSK (0.58) | CTSKCTSBCTSSCTSLABCB1 | |
| SCHEMBL11306127 | 0.89 | CTSK (0.58) | CTSKCTSBCTSSCTSLABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| EP-1294747-B1 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR SA (ES) | 2008-04-30 | — | — | EP | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| CN-1819837-A | TAMANDARIN analogs and fragments thereof and methods of making and using | JOULLIE MADELEINE M (US) | 2006-08-16 | — | — | CN | disclosed |
| EP-0956033-B1 | TOTAL SYNTHESIS OF THE AMINO HIP ANALOGUE OF DIDEMNIN A | UNIV ILLINOIS (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6380156-B1 | HAVING ANTIVIRAL, ANTITUMOR, AND IMMUNOSUPPRESSIVE ACTIVITIES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLNOIS | 2002-04-30 | — | — | US | disclosed |
| WO-1998017302-A9 | TOTAL SYNTHESIS OF THE AMINO HIP ANALOGUE OF DIDEMNIN A | — | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | CTSK 3079/4885CTSB 2140/4885CTSS 3273/4885 |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | FOXM1, F3, RB1 | CTSK 353/4885CTSB 743/4885CTSS 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.